Slide 1: Investor Presentation - June 2025
Investor Presentation - June 2025
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Quest Laboratories Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any sec
Slide 3: Business Overview
Business Overview
Slide 4: Quest at a Glance
Quest at a Glance: 1300 + Licensed Products Capsule Production Line setup is in progress. 2025 capsule production expected revenue 10 Active Products 394 + to 12 Cr’ in this Current year Revenue 3 Year CAGR – 20.4% ROE as of FY25 – 16.6% EBITDA 3 Year CAGR – 35.2% ROCE as of FY25 – 12.1% PAT 3 Year
Slide 5: Company Overview
Company Overview • Quest Laboratories Limited is engaged in the business of manufacturing of pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and
Slide 6: Key Milestone
Key Milestone • Incorporation of our company as private limited company. • ISO 9001 : 2015 In accordance • Good manufacturing practices with the requirements quality Upcoming with Oncology certificate management system standard Injectable with General Line for • Good laboratory practices Added oral
Slide 7: Business Overview: Product Verticals
Business Overview Product Verticals Product wise Revenue Bifurcation - FY25 9% Tablets 10% ORS Powder 8% Tablets Liquid Syrup Dry Syrup 9% 64% Ointment At present having FDA Approvals of more than 900 formulations External Liquids Investor Presentation - March 2024 7
Slide 8: Operational Backbone & Market Approach
Operational Backbone & Market Approach Raw Material Inputs & Sourcing Business Model Key Raw Materials APIs Starting Materials PCD Merchant Government Intermediates Model Export Model Model Region-wise Indirect Participation distribution international in public Supporting Inputs through supply secto
Slide 9: State of Art Manufacturing Facilities
State of Art Manufacturing Facilities Tablet Compressor Tablet Coating Process Powder Mixing Process Processing Manufacturing Plant Our facility is located at Pithampur, Madhya Pradesh, India. CAP Fitting Labeling Suspension Filing Tube Filing Process The total area spans 4,065 square meters. Proces
Slide 10: Pharmaceutical Formulations & Product Capacities
Pharmaceutical Formulations & Product Capacities Antispasmodics Respiratory Medications Formulations Antiemetics Antimalarials Antidepressants Diabetes Treatments Anti-Inflammatories Antiallergic Antispasmodics Antibiotics 1000 Kg + 50,000+ 25,000+ 3000 liters + 9 Million + 1Million + Ointments Syru
Slide 11: Linking Operational Productivity with Revenue Generation
Linking Operational Productivity with Revenue Generation FY24 FY25 Products Capacity Utilization (%) Capacity Utilization (%) Liquid Syrup (In Lakhs Liters) 60 88.48% 60 87.42% Tablets (In Crores) 360 77.27% 360 77.92% Dry Syrup (In Kgs.) 90000 32.26% 90000 32.83% ORS Powder (In Tons) 2700 84.44% 27
Slide 12: Key Managerial Personnel
Key Managerial Personnel Chairman & Managing Director Executive Director Chief Financial Officer Mr. Anil Kumar Sabarwal brings over 25 years Mr. Vinayak Sabarwal completed his primary Mr. Ramkrishna Sharma, completed his Higher of dedicated experience within the same education under the CBSE & M.P.
Slide 13: Geographical Presence
Geographical Presence Pithampur, MP Mali Niger Myanmar Nigeria Thailand Burkina Faso Cambodia Togo Benin Angola International Presence Our company operates in the domestic market across 12 states and 2 union territories. We’ve recently Manufacturing Facility secured an order from Myanmar and have a
Slide 14: Primary Products & Deliverables
Primary Products & Deliverables Investor Presentation - March 2024 14
Slide 15: Proudly Meeting Regulatory Standards
Proudly Meeting Regulatory Standards MSME Zed Bronze Certificate for ISO 9001:2015 Manufacturing, Manufacture of pharmaceuticals, Good Laboratory Practice Good Manufacturing Practice Marketing, Trading medicinal chemical and Certification Certification Pharmaceutical Formulations botanical products
Slide 16: Our Strength's
Our Strength's Versatile Product Capability Dynamic Product Range Growth via Government Partnerships • Holds approvals for over 1300 + formulations. • Diverse portfolio of generics, branded • Participates in government tenders • Manufactures 250-300 formulations pharmaceuticals, OTC products, and an
Slide 17: A Glimpse of Our Recognitions
A Glimpse of Our Recognitions Pharma Industry Excellence Representation at Accredited by the National Title by IPA at the 2024 PharmaLabExpoChem Stock Exchange (NSE) Industrialists Conclave Investor Presentation - March 2024 17
Slide 18: Strategic Overview
A vi Strategic : Overview
Slide 19: Future Targets
Future Targets Expanding into advanced injectables with a focus on high-quality vials, ampoules, and innovative lyophilizer technology. Launching a new collagen product line to Expanding manufacturing capacity diversify the portfolio and meet growing with the addition of two new market demand. Advan
Slide 20: Industry Overview
Industry Overview
Slide 21: India Pharmaceutical Industry
India Pharmaceutical Industry India Pharmaceutical Market US$ Billion Evolution Of Pharma Industry: Small Molecules To Next-generation Therapeutics 450F Small Molecules Biologics and Targeted Next-gen Therapeutics (New Modalities) (1950s) Therapies (1980s) (2000s) (2015+) (2020+) 270F Cell and Antib
Slide 22: India's Strategic Edge in Pharmaceuticals
India’s Strategic Edge in Pharmaceuticals Increasing Investment Policy Support • India permits 100% FDI in Greenfield pharma and up to • Rs. 500 crore scheme “Strengthening of Pharmaceutical 74% in Brownfield, with higher stakes needing Industry” supports pharma clusters and M S M E s to government
Slide 23: Half-Yearly Financial Overview
Half-Yearly Financial Overview
Slide 24: Financial Highlights
Financial Highlights Particulars (INR Lacs) H2 FY25 H2 FY24 Y-o-Y H1 FY25 H-o-H FY25 FY24 Y-o-Y Revenue from Operations 6,128.9 4,262.6 43.8% 4,154.6 47.5% 10,391.5 8,256.3 25.9% Total Raw Material 5,523.8 2,392.0 2,641.7 7,915.9 5,224.5 Gross Profit 605.1 1,870.6 -67.7% 1,512.9 -60.0% 2,475.6 3,031
Slide 25: Financial Performance
Financial Performance ASSETS (INR Lacs) Mar-25 Mar-24 EQUITY AND LIABILITIES ( (INR Lacs) Mar-25 Mar-24 Non ‐ Current Assets Shareholders Fund a) Share capital 1638.72 1193.76 a) Property, plant and equipment 1178.73 1023.94 b) Reserves and surplus 6541.62 1673.05 b) Non-Current Investments 291.59 T
Slide 26: Historical Cash Flow Statement
Historical Cash Flow Statement Particulars (INR Cr) Mar-25 Mar-24 Cash Flow from Operating Activities Profit before Tax 1868.31 1444.59 Adjustment for Non-Operating Items -269.49 110.26 Operating Profit before Working Capital Changes 1598.82 1554.85 Changes in Working Capital -3538.03 -832.85 Cash G
Slide 27: Historical Financial Overview
Historical Financial Overview
Slide 28: Key Financial Metrics
Key Financial Metrics Revenue (INR Lacs) EBITDA (INR Lacs) and EBITDA Margin (%) PAT (INR Lacs) and PAT Margin (%) 10,392 1,555 1,598 1,357 8,256 6,164 1,009 784 18.83% 15.38% 13.05% 505 12.23% 12.73% 8.18% FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 Revenue Growth EBITDA Growth PAT Growth +44% +3%
Slide 29: Segment-Wise Revenue Bifurcation
Segment-Wise Revenue Bifurcation Tablets (INR Cr) Syrup (INR Cr) Suspension (INR Cr) 9 67 16 14 49 50 44 9 10 25 4 2 2 1 1 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Ointments (INR Cr) ORS (INR Cr) 10 8 6 8 2 1 1 0 0 0 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25
Slide 30: Historical Income Statement
Historical Income Statement Particulars (INR Lacs) Mar-23 Mar-24 Mar-25 Revenue from Operations 6164.1 8256.3 10391.5 Total Raw Material 4179.8 5224.5 7915.9 Gross Profit 1984.3 3031.8 2475.6 Gross Profit Margin (%) 32.19% 36.72% 23.82% Employee Expenses 334.1 427.3 427.7 Other Expenses 865.7 1049.6
Slide 31: Historical Balance Sheet
Historical Balance Sheet ASSETS (INR Lacs) Mar-23 Mar-24 Mar-25 EQUITY AND LIABILITIES ( (INR Lacs) Mar-23 Mar-24 Mar-25 Shareholders Fund Non ‐ Current Assets a) Share capital 107.88 1193.76 1638.72 a) Property, plant and equipment 983.94 1023.94 1178.73 b) Reserves and surplus 1402.07 1673.05 6541
Slide 32: Historical Cash Flow Statement
Historical Cash Flow Statement Particulars (INR Cr's) Mar-23 Mar-24 Mar-25 Cash Flow from Operating Activities Profit before Tax 698.17 1444.59 1868.31 Adjustment for Non-Operating Items 86.28 110.26 -269.49 Operating Profit before Working Capital Changes 784.45 1554.85 1598.82 Changes in Working Ca
Slide 33: Way Ahead
Way Ahead
Slide 34: Path to Growth, Scale & Profitability
Path to Growth, Scale & Profitability Oncology and Injectables expansion moving rapidly with land acquired at Plot 44, Pithampur on 7th April 2025 and pharma consultant engaged to commence plant design. Growth Acceleration Focused expansion, aimed at driving EBITDA margin recovery back to the 18–20%
Slide 35: Thank You
Company : Quest Laboratories Limited CIN: U24232MP1998PLC012850 Email ID: cmd@questlabltd.com Tel: +91-9329095934 Thank You Website: www.questlabltd.com Investor Relations Partner : X-B4 Advisory LLP Rasika Sawant / Divya Shethia Tel: +91 95944 57518 / 8850595811 Email ID: rasika@x-b4.com Website: w